2 Beaten-Down GLP-1 Stocks to Buy on the Dip
The GLP-1 market is currently one of the fastest-growing areas in the pharmaceutical industry. It’s not surprising, then,…
Is Kailera Therapeutics a Buy After Its Sizzling IPO?
Key Points The GLP-1 drug market could be worth $190 billion by 2035. Kailera Therapeutics has several weight-loss…
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a…
All Eyes on Copenhagen for Neurodegenerative Disease Data
Denali Therapeutics’ stock surges 32.6% ahead of a pivotal data showcase at the AD/PD 2026 conference, where validation…
Neutron Therapeutics and Helsinki University Hospital Hold Ribbon Cutting Ceremony for Europe’s first In-Hospital Boron Neutron Capture Therapy Facility
Attendees celebrated the accomplishments of a 10-year collaboration leading to the first patients treated in 2025 The first…